Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 99

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 99
---
) $100,794 from the cash exercise of the February 2025 Placement Agent Warrants. The holders of the Common Warrants and the Placement Agent Warrants are not obligated to exercise the warrants, and we cannot predict whether or when, if ever, the holders of the warrants will choose to exercise their respective warrants, in whole or in part. Any proceeds from such exercise will be used for general corporate purposes and working capital. 57 DIVIDEND POLICY We have not declared any cash dividends since inception and we do not anticipate paying any dividends in the foreseeable future. Instead, we anticipate that all of our earnings will be used to provide working capital, to support our operations, and to finance the growth and development of our business. The payment of dividends is within the discretion of the Board and will depend on our earnings, capital requirements, financial condition, prospects, operating results, cash needs, growth plans, applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits, and other factors our board might deem relevant. There are no restrictions that currently limit our ability to pay dividends on our common stock other than those generally imposed by applicable state law. CAPITALIZATION The following table sets forth our consolidated cash, cash equivalents and short-term investments and capitalization, as of December 31, 2024. Such information is set forth on the following basis:

| ● | on an actual basis;                                                                                                                  |
| ● | on a pro forma basis to reflect the issuance of (i) 15,809 shares issued to our officers as 2024                                     
 bonuses, (ii) 385,200 shares issued for the exercise of 385,200 pre-funded warrants after December 31, 2024 but prior to the date    
 of this prospectus supplement, (iii) 204,312 shares of common stock issued in the January 2025 Offering based on the offering price  
 of $5.105 per share of common stock net of certain offering expenses, and (iv) 300,700 shares of common stock issued in the February 
 2025 Offering based on the offering price of $3.575 per share of common stock net of certain offering expenses; and                  |

| ● | on a pro forma as adjusted basis to reflect our receipt of the gross proceeds from the full exercise                              
 of the Common Warrants and the Placement Agent Warrants resulting in the issuance of 747,200 shares of common stock at a weighted 
 average exercise price of $3.561 per share.